The Role of Cyfra 21-1 in Head and Neck Cancer
Author Information
Author(s): Doweck I, Barak M, Uri N, Greenberg E
Primary Institution: Department of Otolaryngology, Head and Neck Surgery, Carmel Medical Center
Hypothesis
Can Cyfra 21-1 levels predict survival and recurrence in head and neck cancer patients?
Conclusion
Cyfra 21-1 is a useful prognostic marker for head and neck cancer, indicating survival rates and potential recurrence.
Supporting Evidence
- Patients with Cyfra 21-1 levels below 1.5 ng ml–1 had a 63% survival rate.
- Patients with Cyfra 21-1 levels at or above 1.5 ng ml–1 had a 20% survival rate.
- 83% of patients with recurrent disease had elevated Cyfra 21-1 levels before clinical detection.
Takeaway
This study found that a blood test for a marker called Cyfra 21-1 can help doctors understand how well patients with head and neck cancer might do and if their cancer might come back.
Methodology
The study evaluated 67 patients with head and neck cancer, measuring Cyfra 21-1 levels and correlating them with survival and disease recurrence.
Participant Demographics
Patients with primary detection of carcinoma of head and neck.
Statistical Information
P-Value
0.028
Statistical Significance
p=0.028
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website